Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2011
Executive Summary
Biopharma financing dropped in Q3 2011 to $1.3 billion, down from $6.3 billion in Q2. There were 20 M&A deals that totaled $30.9 billion, attributed mainly to the $27.7 million merger of PBMs Express Scripts and Medco. Almost a quarter of the alliances penned were for preclinical assets.
You may also be interested in...
Shareholder Revolt at AMAG Squelches All-Stock Merger with Equally Struggling Allos
AMAG shareholders have killed plans for what they considered an ill-conceived merger and one shareholder calls the vote a "clear signal" that current management isn't fit to run the company.
Asia Spotlight: Meet China’s New Innovators – Hua Medicine Looks To Take Flight With U.S. Venture Backing
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. launched in August 2011 as a spin out of Vantia Therapeutics. KalVista acquired a portfolio of small-molecule plasma kallikrein inhibitors from Vantia's preclinical store. The compounds will be developed to treat diabetic macular edema, a condition that threatens the vision of up to a quarter of the world's 285 million diabetes sufferers.